MALVERN, Pa., April 18, 2022 (Globe NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-phase medical technology enterprise targeted on furnishing modern gentle-tissue reconstruction methods that improve medical results by prioritizing the preservation and restoration of the patient’s individual anatomy, these days declared the selecting of D. Taylor Ocasio as the Company’s new Typical Counsel (GC). As GC, Mr. Ocasio will guide the Firm’s authorized and governance attempts.
Mr. Ocasio joins TELA with practically ten decades of corporate lawful functions and healthcare industry practical experience. Most just lately, Mr. Ocasio served as Deputy Basic Counsel of Zynerba Prescribed drugs, a scientific-stage specialty pharmaceutical business, the place he helped guide the authorized functions and compliance packages. Prior to that, Mr. Ocasio served as Assistant General Counsel of Catalent Pharma Remedies, a world provider of biopharma, cell, gene, and shopper health and fitness products and solutions, supporting its Biologics, Gene and Cell treatment business device. Mr. Ocasio also held Associate and Senior Associate positions with Pepper Hamilton LLP and Hogan Lovells US LLP in their Wellness Science and Corporate Securities tactics. Mr. Ocasio been given a Bachelor of Arts from The Ohio Point out University and a Juris Health care provider diploma from Drexel University’s Thomas R. Kline College of Regulation.
“I am greatly happy to have Taylor on the TELA Bio crew. He delivers a abundant breadth of knowledge and encounter to the job and will be a worthwhile addition to the Corporation,” claimed Antony Koblish, president and CEO of TELA Bio. “His extensive know-how of lifetime sciences and company securities will be an asset to TELA as we carry on to increase an extremely strong crew.”
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage clinical technologies firm concentrated on providing impressive systems that optimize scientific outcomes by prioritizing the preservation and restoration of the patient’s have anatomy. The Company is committed to supplying surgeons with state-of-the-art, economically productive delicate-tissue reconstruction answers that leverage the patient’s pure healing reaction although reducing lengthy-phrase exposure to long lasting synthetic supplies. For a lot more information and facts, go to www.telabio.com.
Warning Concerning Ahead-Looking Statements
This press release has forward-looking statements within just the that means of The Private Securities Litigation Reform Act of 1995. Terms these as “could,” “may possibly,” “will,” “should really,” “consider,” “expect,” “foresee,” “estimate,” “continue,” “predict,” “forecast,” “project,” “approach,” “intend” or similar expressions, or statements with regards to intent, belief, or existing anticipations are forward-wanting statements and reflect the latest beliefs of TELA’s management. These statements are not guarantees of long run efficiency and are matter to sure threats, uncertainties and other things that could cause genuine effects and gatherings to differ materially and adversely from those indicated by these ahead-seeking statements. These dangers and uncertainties are explained more thoroughly in the “Threat Aspects” part and somewhere else in our filings with the Securities and Exchange Fee and obtainable at www.sec.gov, which include in our Once-a-year Report on Sort 10-K and Quarterly Studies on Sort 10-Q. Any forward-searching statements that we make in this announcement converse only as of the day of this push launch, and TELA assumes no obligation to update forward-hunting statements no matter if as a result of new details, long term events or if not just after the date of this press release, other than as demanded underneath relevant regulation.
Investor Call
Greg Chodaczek
332-895-3230
[email protected]
